Svetlana Gelperina

List of Publications by Year
in descending order

46 papers	5,199 citations	172457 29 h-index	233421 45 g-index
47 all docs	47 docs citations	47 times ranked	6179 citing authors

#	Article	IF	Citations
1	Transport of drugs across the bloodâ€"brain barrier by nanoparticles. Journal of Controlled Release, 2012, 161, 264-273.	9.9	584
2	The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1487-1490.	5.6	579
3	Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research, 1999, 16, 1564-1569.	3.5	468
4	Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. International Journal of Cancer, 2004, 109, 759-767.	5.1	414
5	Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharmaceutical Research, 2003, 20, 409-416.	3.5	404
6	Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Td (117, 51-58.	9.9	287
7	Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 157-163.	4.3	260
8	Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. Journal of Controlled Release, 2007, 118, 54-58.	9.9	247
9	Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. Journal of Drug Targeting, 2009, 17, 564-574.	4.4	198
10	Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicology Letters, 2002, 126, 131-141.	0.8	186
11	Efficient Chemotherapy of Rat Glioblastoma Using Doxorubicin-Loaded PLGA Nanoparticles with Different Stabilizers. PLoS ONE, 2011, 6, e19121.	2.5	138
12	Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Journal of Drug Targeting, 2006, 14, 97-105.	4.4	122
13	Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells. International Journal of Pharmaceutics, 2017, 524, 77-90.	5.2	122
14	Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. International Journal of Pharmaceutics, 2007, 345, 154-162.	5.2	114
15	Use of Nanoparticles for Cerebral Cancer. Tumori, 2008, 94, 271-277.	1.1	111
16	Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.8	92
17	Kinetics of transport of doxorubicin bound to nanoparticles across the bloodâ€"brain barrier. Journal of Controlled Release, 2011, 154, 103-107.	9.9	91
18	Adsorption of plasma proteins on uncoated PLGA nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 53-60.	4.3	75

#	Article	IF	Citations
19	Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: Towards the pharmaceutical development. International Journal of Pharmaceutics, 2019, 572, 118733.	5.2	74
20	Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. International Journal of Pharmaceutics, 2007, 337, 346-356.	5.2	66
21	Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. International Journal of Pharmaceutics, 2019, 554, 161-178.	5.2	52
22	Transferrin-Coated Gadolinium Nanoparticles as MRI Contrast Agent. Molecular Imaging and Biology, 2013, 15, 148-154.	2.6	48
23	Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. Journal of Drug Targeting, 2006, 14, 614-622.	4.4	47
24	Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicology Letters, 2008, 178, 9-19.	0.8	42
25	The bloodâ€“brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 359-379.	3.3	41
26	Radiation sterilisation of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles. International Journal of Pharmaceutics, 2008, 356, 325-332.	5.2	40
27	Use of nanoparticles for cerebral cancer. Tumori, 2008, 94, 271-7.	1.1	34
28	Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 132-141.	4.3	33
29	Nanoparticle-based delivery of carbamazepine: A promising approach for the treatment of refractory epilepsy. International Journal of Pharmaceutics, 2018, 547, 10-23.	5.2	31
30	Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging. Journal of Controlled Release, 2015, 199, 63-71.	9.9	29
31	Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A. Journal of Controlled Release, 2017, 253, 1-10.	9.9	29
32	How subtle differences in polymer molecular weight affect doxorubicin-loaded PLGA nanoparticles degradation and drug release. Journal of Microencapsulation, 2020, 37, 283-295.	2.8	23
33	Release kinetics of fluorescent dyes from PLGA nanoparticles in retinal blood vessels: In vivo monitoring and ex vivo localization. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 150, 131-142.	4.3	17
34	Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin. Molecules, 2021, 26, 831.	3.8	17
35	Encapsulation of Water-Insoluble Drugs in Poly(butyl cyanoacrylate) Nanoparticles. Journal of Nanoscience and Nanotechnology, 2009, 9, 5091-5098.	0.9	16
36	Injectable drug delivery systems of doxorubicin revisited: In vitro-in vivo relationships using human clinical data. International Journal of Pharmaceutics, 2021, 608, 121073.	5.2	15

#	Article	IF	Citations
37	A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, e13537-e13537.	1.6	13
38	Fluorescently Labeled PLGA Nanoparticles for Visualization In Vitro and In Vivo: The Importance of Dye Properties. Pharmaceutics, 2021, 13, 1145.	4.5	12
39	Increased Numbers of Injections of Doxorubicin Bound to Nanoparticles Lead to Enhanced Efficacy Against Rat Glioblastoma 101/8. Journal of Nanoneuroscience, 2009, 1, 144-151.	0.5	10
40	Contrast Enhancement of the Brain by Folate-Conjugated Gadoliniumâ€“Diethylenetriaminepentaacetic Acidâ€“Human Serum Albumin Nanoparticles by Magnetic Resonance Imaging. Molecular Imaging, 2012, 11, 7290.2011.00047.	1.4	8
41	Quantitative analysis of palladacycle-tagged PLGA nanoparticle biodistribution in rat organs by means of atomic absorption spectrometry and inductively coupled plasma mass spectrometry. Journal of Analytical Atomic Spectrometry, 2021, 36, 2423-2430.	3.0	5
42	Brain Delivery by Nanoparticles. Drugs and the Pharmaceutical Sciences, 2006, , .	0.1	2
43	Comparative morphological and biochemical characteristics of the toxic effects of doxorubicin and nanosomal PLGA-doxorubicin form in the experimental glioblastoma treatment. Clinical and Experimental Morphology, 2021, 10, 58-65.	0.2	1
44	Exploring the systemic delivery of a poorly water-soluble model drug to the retina using PLGA nanoparticles. European Journal of Pharmaceutical Sciences, 2021, 164, 105905.	4.0	1
45	Optimization of Methods for Determination of the Encapsulation Efficiency of Doxorubicin in the Nanoparticles Based on Poly(lactic-co-glycolic acid) (PLGA). Drug Development and Registration, 2020, 9, 113-118.	0.6	0
46	CYTOTOXICITY AND HEMOCOMPATIBILITY OF DOXORUBICIN-LOADED PLGA NANOPARTICLES. , 2020, 19, 71-80.	0.3	0